Newer antidiabetic drugs might improve steatosis: study

Researchers have conducted a meta-analysis of studies covering four therapies
Reuters Health Staff writer
packets of pills of different types

Early evidence suggests that newer diabetes drugs might improve liver enzymes and hepatic steatosis and could perhaps be of use in treating non-alcoholic fatty liver disease (NAFLD), researchers say.

Pakistani researchers searched the literature to May 2020 for randomised clinical trials assessing the efficacy of glucagon-like peptide-1 (GLP-1) agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, pioglitazone and dipeptidyl-peptidase-4 (DPP-4) inhibitors in treating NAFLD.